TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22222634

Group type: EXPERIMENTAL
Intervention: Perampanel (4 mg/d)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each dose of L-dopa)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study: 20574018

Group type: EXPERIMENTAL
Intervention: Topical 0.45% OT-551 administered three times daily for 2 years
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 10
Study: 18056100

Group type: EXPERIMENTAL
Intervention: Modified Widman flap (MWF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Flap with osseous resection (OF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Gingivectomy (GV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All surgical procedures
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 56
Study: 16129715

Group type: EXPERIMENTAL
Intervention: Forskolin (250 mg of 10% forskolin extract twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12405362

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g IV as soon as SAH diagnosis was verified, followed by 1 g every 6 hours until aneurysm occlusion, not exceeding 72 hours)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid treatment)
Number of subjects: 505
Study: 10091409

Group type: EXPERIMENTAL
Intervention: Tc99m‐sestaMIBI scintigraphy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional Xr
Number of subjects: 55
Study: 7771608

Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Monospecific antivenom (AVS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment with AVS
Number of subjects: 50
Study: 2124756

Group type: EXPERIMENTAL
Intervention: verapamil, 10 mg in 5 minutes (n = 29)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: flecainide, 2 mg/kg in 10 minutes (n = 20)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: propafenone, 2 mg/kg in 10 minutes (n = 20)
Number of subjects: 69
Study: 463537

Group type: EXPERIMENTAL
Intervention: Induction of labour by amniotomy and intravenous oxytocin infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spontaneous labour followed by amniotomy (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Induction and Control)
Number of subjects: 80
Study: 31346896

Group type: EXPERIMENTAL
Intervention: Cumulative GCPC risk score based on demographic/tumor characteristics
Number of subjects: 4285
Study: 30055127

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28499363

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (n = 47)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Rocker‐sole footwear (n = 41)
Number of subjects: 88
Study: 25623736

Group type: EXPERIMENTAL
Intervention: Cognitive remediation plus standard treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 126
Study: 22542709

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 20638813

Group type: EXPERIMENTAL
Intervention: Message emphasizing the value of patient-centeredness
Number of subjects: 384

Group type: COMPARATOR
Intervention: Neutral message
Number of subjects: 384

Group type: COMPARATOR
Intervention: Message emphasizing technical competence
Number of subjects: 384
Study: 18401974

Group type: EXPERIMENTAL
Intervention: Single intravaginal dose of Polyhexamethylene Biguanide (PHMB)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Seven daily doses of Clindamycin vaginal cream
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Single intravaginal dose of Polyhexamethylene Biguanidine (PHMB)
Number of subjects: 740
Study: 16326006

Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in SNP8NRG241930
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in SNP8NRG243177
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygotes of minor alleles in rs1081062
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haplotype constructed from four SNPs
Number of subjects: 0
Study: 14687261

Group type: EXPERIMENTAL
Intervention: Active learning curriculum using standardized patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11198264

Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1,000 mg ascorbic acid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5,000 mg ascorbic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (all doses)
Number of subjects: 20
Study: 9160496

Group type: EXPERIMENTAL
Intervention: Treatment among compliers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intent-to-treat analysis
Number of subjects: 0
Study: 8416762

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5‐10 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nadolol 40‐160 mg once daily
Number of subjects: 80
Study: 3091718

Group type: EXPERIMENTAL
Intervention: Mucin-containing saliva substitute
Number of subjects: 42

Group type: COMPARATOR
Intervention: CMC-containing saliva substitute
Number of subjects: 42
Study: 29657205

Group type: EXPERIMENTAL
Intervention: Xyla-P cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold compress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 27002783

Group type: EXPERIMENTAL
Intervention: Overdose Education (OE) intervention (small group lecture, slideshow, and handout)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Historical non-intervention control group
Number of subjects: 43
Study: 25565669

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Limited Sampling Strategies (LSS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Validation group
Number of subjects: 38
Study: 23559222

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral yohimbine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 20213026

Group type: EXPERIMENTAL
Intervention: Thin ultrasonic tip
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional tip
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 19134065

Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Redon bottles
Number of subjects: 10
Study: 15901043

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice daily, n = 7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg once daily for two days and thereafter 25 mg daily, n = 7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once daily, n = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12687534

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg daily by subcutaneous injection)
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study: 10797162

Group type: EXPERIMENTAL
Intervention: Early hospital discharge and home‐based rehabilitation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional in‐hospital rehabilitation and community care
Number of subjects: 86
Study: 8635937

Group type: EXPERIMENTAL
Intervention: Olsalazine 250 mg, two capsules twice daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo, two capsules twice daily
Number of subjects: 58
Study: 1615937

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with absolute alcohol (group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional therapy (blood transfusions, antacids, and ranitidine) (group 2)
Number of subjects: 39
Study: 6435856

Group type: EXPERIMENTAL
Intervention: LMS (+) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMS (−) regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (LMS (+) and LMS (−))
Number of subjects: 0
Study: 29950147

Group type: EXPERIMENTAL
Intervention: End-of-life care provided by assistant nurses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Experience-based knowledge in end-of-life care
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Attentive end-of-life care focusing on bodily care
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Support and education for assistant nurses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Organizational support for care
Number of subjects: 7
Study: 28548556

Group type: EXPERIMENTAL
Intervention: Modified physical education unit (mountain biking)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard physical education
Number of subjects: 300

Group type: COMPARATOR
Intervention: No physical education
Number of subjects: 300
Study: 27507807

Group type: EXPERIMENTAL
Intervention: Nurse case management and outreach notifications for STIs at 1 and 3 months
Number of subjects: 153
Study: 25316469

Group type: EXPERIMENTAL
Intervention: Regular intermittent bolus (RIB) - 10 ml of 0.08% ropivacaine + 0.4 ug·ml‐1 sufentanil administered once an hour
Number of subjects: 132

Group type: COMPARATOR
Intervention: Continuous infusion (CI) - same solution continuously infused at a rate of 10 ml·h‐1
Number of subjects: 132
Study: 22972817

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 434

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: hVISA strains (14.5%)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: CC5
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: CC8
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: CC239
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: USA300
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: hVISA prevalence
Number of subjects: 434
Study: 19362290

Group type: EXPERIMENTAL
Intervention: V-Y advancement flap (VYAF)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Simple primary closure (AL group)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Simple primary closure (SS group)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 238
Study: 17278988

Group type: EXPERIMENTAL
Intervention: Valsartan (VAL)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Combined cardiovascular endpoints
Number of subjects: 659
Study: 15643212

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 79
Study: 11863247

Group type: EXPERIMENTAL
Intervention: Reduced alcohol period
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual alcohol period
Number of subjects: 33
Study: 10410207

Group type: EXPERIMENTAL
Intervention: Treatment A (diaphragm breathing with incentive spirometry and postural drainage)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment B (diaphragm breathing with positive expiratory pressure (PEP-mask) and postural drainage)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study: 7774781

Group type: EXPERIMENTAL
Intervention: Prenatal parenting communication classes (two second-trimester classes)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 1566987

Group type: EXPERIMENTAL
Intervention: Loss of resistance to saline technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraesthesia technique
Number of subjects: 0
Study: 4014868

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30797673

Group type: EXPERIMENTAL
Intervention: External cold and vibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blowing soap bubbles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30077350

Group type: EXPERIMENTAL
Intervention: 800 mg intravenous ibuprofen in 100 mL saline solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: 100 mL intravenous saline solution
Number of subjects: 50
Study: 28007113

Group type: EXPERIMENTAL
Intervention: NSAID (bromfenac 0.1% [Bronuck])
Number of subjects: 59

Group type: COMPARATOR
Intervention: Steroid (prednisolone acetate 1.0% [Pred Forte])
Number of subjects: 59
Study: 24491639

Group type: EXPERIMENTAL
Intervention: 50% glucose eye drops
Number of subjects: 29

Group type: COMPARATOR
Intervention: 0.9% saline eye drops
Number of subjects: 29
Study: 22143717

Group type: EXPERIMENTAL
Intervention: AH 26 + gutta‐percha
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH 26 + BeeFill
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH 26 + Thermafil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Instrumentation (no filling)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-prepared group
Number of subjects: 80
Study: 20382089

Group type: EXPERIMENTAL
Intervention: FTW learner‐centered fruit and vegetable class
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 60
Study: 18407313

Group type: EXPERIMENTAL
Intervention: Random jittering of orthogonal property (width, aspect ratio, area)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unjittered trials
Number of subjects: 0
Study: 15816575

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with initial effect site concentration of 1.5 ng mL(‐1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fentanyl TCI with initial effect site concentration of 2 ng mL(‐1)
Number of subjects: 44
Study: 11952049

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy to one randomly selected orbit
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham radiotherapy to the other side
Number of subjects: 42
Study: 9771182

Group type: EXPERIMENTAL
Intervention: 15 micrograms (0.3 ml) fentanyl added to 2.5 ml 0.5% hyperbaric bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3 ml 0.9% saline (control group)
Number of subjects: 40
Study: 7930890

Group type: EXPERIMENTAL
Intervention: Telfa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraffin gauze
Number of subjects: 0

Group type: COMPARATOR
Intervention: BIPP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 0
Study: 2979003

Group type: EXPERIMENTAL
Intervention: Phenylephrine hydrochloride 2.5% and 10% for muscle stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Guanethidine 5% and thymoxamine hydrochloride 0.5% for muscle inhibition
Number of subjects: 10
Study: 31912391

Group type: EXPERIMENTAL
Intervention: Soil profiles under trees (site 2 and 5)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Open field (sites 1, 3, 4 and 6)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Top soil layers
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soil profiles under trees
Number of subjects: 6
Study: 29482525

Group type: EXPERIMENTAL
Intervention: Internet-based grief therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 27562481

Group type: EXPERIMENTAL
Intervention: High-egg diet (> 4 eggs per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-egg diet (1-3 eggs per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Egg-free diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal egg ingestion
Number of subjects: 0
Study: 24713286

Group type: EXPERIMENTAL
Intervention: Compound whole grain-soybean
Number of subjects: 163

Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 163
Study: 24071752

Group type: EXPERIMENTAL
Intervention: Health education program consisting of five sessions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study: 20575206

Group type: EXPERIMENTAL
Intervention: Transbond XT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Blūgloo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: BeautyOrtho Bond
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Enlight
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Light Bond
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Transbond CC
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Xeno Ortho
Number of subjects: 140
Study: 16936646

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 34
Study: 17012900

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine plus SRL 172
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hepatitis B vaccine plus placebo
Number of subjects: 58
Study: 14555586

Group type: EXPERIMENTAL
Intervention: Respiratory relaxation feedback (RFB) during CO(2) rebreathing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CO(2) trial session and CO(2) RFB session
Number of subjects: 24

Group type: COMPARATOR
Intervention: CO(2) trial session and CO(2) no-feedback (NFB) session
Number of subjects: 24
Study: 10757582

Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anaesthesia (HEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal anaesthesia (SPA)
Number of subjects: 30
Study: 8936627

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chlormadinone 50 mg daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin 0.2 mg and chlormadinone 50 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and chlormadinone 50 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 80
Study: 8447241

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 100
Study: 3532763

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 1273
Study: 29593013

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (FH)
Number of subjects: 106412

Group type: EXPERIMENTAL
Intervention: High LDL cholesterol
Number of subjects: 106412

Group type: EXPERIMENTAL
Intervention: Clinical FH criteria including personal premature ischemic heart disease
Number of subjects: 106412

Group type: EXPERIMENTAL
Intervention: Ischemic heart disease at baseline
Number of subjects: 106412
Study: 27538423

Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (CLI) for 1 year
Number of subjects: 381

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 381
Study: 24116868

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ustekinumab dose adjustment to 90 mg
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall population)
Number of subjects: 489
Study: 22717177

Group type: EXPERIMENTAL
Intervention: NRF education group
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study: 20298928

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 18220486

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg b.i.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg/day
Number of subjects: 9
Study: 15819761

Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nefopam 10 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 89
Study: 12640329

Group type: EXPERIMENTAL
Intervention: Blue coloured placebo for anxious patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Red coloured placebo for tired patients
Number of subjects: 34
Study: 9872878

Group type: EXPERIMENTAL
Intervention: Reviewers asked to be identified
Number of subjects: 125

Group type: COMPARATOR
Intervention: Anonymous reviewers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Editors' quality score for reviews
Number of subjects: 125
Study: 8951965

Group type: COMPARATOR
Intervention: Intravenous fentanyl (0.1 mg/70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.5, 1, and 2 mg per 70 kg) with fentanyl
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam (combined with fentanyl)
Number of subjects: 12
Study: 1937995

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg intravenously every 8 hours for 3 days, then 150 mg orally in the evening for one month)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 7380586

Group type: COMPARATOR
Intervention: Proquazone (600 mg) after 20 ml of antacid (Maaloxan)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Proquazone (600 mg) after a standard breakfast
Number of subjects: 12
Study: 31763228

Group type: EXPERIMENTAL
Intervention: Lipid based ointment with tablet Rupatidine 10 mg OD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tablet Rupatidine 10 mg OD alone
Number of subjects: 60
Study: 27029957

Group type: EXPERIMENTAL
Intervention: Plyometric exercise (plate jump) during warm-up
Number of subjects: 10

Group type: COMPARATOR
Intervention: No plyometric exercise during warm-up
Number of subjects: 10
Study: 26300796

Group type: EXPERIMENTAL
Intervention: Computer-based auditory training (CBAT) for 4 weeks, focusing on phoneme discrimination.
Number of subjects: 44